Compare Iron Mountain Inc (IRM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Iron Mountain (IRM) trades at $115.73, down 0.66% on the day, with a bullish technical signal and strong analyst consensus. The company reported revenue growth to $6.90B in 2025, though net income margin compressed to 2.09%. Recent news highlights expansion in data centers and digital partnerships, while institutional investors like Bank of America and California State Teachers Retirement System increased holdings significantly in Q2 2026.

The outlook remains positive with a consensus price target of $142.75 implying 23% upside, supported by data center pipeline growth and digital cross-selling. Key risks include high debt levels with a debt-to-asset ratio of 79.04% in 2025 and margin pressure from rising interest expenses. Earnings beats in recent quarters reinforce execution strength, but valuation multiples like a P/E of 82.09 demand sustained growth.

Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.

The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.